Data di Pubblicazione:
2012
Citazione:
Trastuzumab containing regimens for early breast cancer / L. Moja, L. Tagliabue, S. Balduzzi, E. Parmelli, V. Pistotti, V. Guarneri, R. D'Amico. - In: COCHRANE DATABASE OF SYSTEMATIC REVIEWS. - ISSN 1469-493X. - 2012:4(2012 Apr), pp. CD006243.1-CD006243.85.
Abstract:
Approximately one-fifth of women who develop early breast cancer have HER2-positive tumours, which if untreated, have a worse prognosis than HER2-negative tumours. Trastuzumab is a selective treatment targeting the HER2 pathway. Although the results on efficacy seem to support its use, there are potential cardiac toxicities which need to be considered, especially for women at lower risk of recurrence, or those at increased cardiovascular risk.
Tipologia IRIS:
01 - Articolo su periodico
Elenco autori:
L. Moja, L. Tagliabue, S. Balduzzi, E. Parmelli, V. Pistotti, V. Guarneri, R. D'Amico
Link alla scheda completa: